KRAS and colorectal carcinoma: Overall these findings, besides confirming the lack of response to cetuximab in CRC cells with KRAS, BRAF and PIK3CA mutations, indicate that gabexate mesilate is able to exert a significant antitumoral activity in CRC cells harbouring either wild-type or mutated KRAS, BRAF and PIK3CA genes, with an efficacy comparable to that observed when it is used in combination with anti-EGFR antibodies.